Description
Lorazepam Tablet
Lorazepam Tablets USP / BP / IP (0.5 mg / 1.0 mg / 2.0 mg)
High-Precision Benzodiazepine Anxiolytic & Anticonvulsant
Healthy Life Pharma Private Limited, alongside our specialized global export and marketing division Healthy Inc, is an authorized manufacturer, CDMO partner, and wholesale supplier of advanced neurology, psychiatry, and central nervous system (CNS) therapeutics. We manufacture ultra-high-purity, kinetically stable Lorazepam Tablets within our state-of-the-art, WHO–GMP certified, high-containment psychotropic manufacturing installations.
As a primary clinical choice for immediate neuro-psychiatric stabilization, this product serves as a vital strategic export to hospital emergency networks, psychiatric clinic chains, state tender procurement lines, and international B2B pharmaceutical marketplaces across the CIS region, Africa, LATAM, and South-East Asia.
Product Overview
This formulation operates as a “Central Nervous System Gating Adjuvant.” It ensures patient safety and rapid calming during acute neurological crises by amplifying the brain’s internal inhibitory signaling pathways.
Mechanism 1 (GABA-A Receptor Allosteric Modulation): Lorazepam physically binds with high affinity to specific benzodiazepine receptor sites located allosterically on postsynaptic $\text{GABA}_{\text{A}}$ receptor-chloride channel complexes within the central nervous system.
Mechanism 2 (Chloride Influx Hyperpolarization): This physical binding chemically enhances the inhibitory effects of gamma-aminobutyric acid ($\text{GABA}$). It increases the frequency of the chloride channel opening window, physically forcing an influx of negatively charged chloride ions into the post-synaptic neuron.
Mechanism 3 (Neuronal Hyperexcitability Suppression): The massive chloride influx chemically shifts the membrane potential into a state of hyperpolarization. This physically elevates the firing threshold of the neuron, suppressing chaotic, repetitive electrical discharges to immediately damp down acute panic, muscle spasms, and seizure propagation.
Product Composition & Available Strengths
We supply Lorazepam across the complete, internationally standardized therapeutic spectrum to allow for safe dose titration and exact behavioral control.
| Active Ingredient Monograph | Available Strengths | Formulation Matrix Delivery System | Primary Clinical Target |
| Lorazepam USP / BP / IP | 0.5 mg | Oral / Sublingual Micro-Tablet | Mild Anxiety & Pediatric Titration: For delicate introductory dosing and generalized anxiety management. |
| Lorazepam USP / BP / IP | 1.0 mg | Oral / Sublingual Micro-Tablet | Foundation Anxiolytic / Insomnia: Standard baseline dosage for acute panic control and pre-operative sedation. |
| Lorazepam USP / BP / IP | 2.0 mg | Oral High-Potency Solid Tablet | Critical Care Stabilization: For intensive management of acute manic states, alcohol withdrawal delirium, and status epilepticus. |
Technical & Logistics Specifications
HS Code: 3004.90.99 (Medicaments acting on the central nervous system / Psychotropics / Benzodiazepines)
CAS Number: 846-49-1 (Lorazepam)
Dosage Form: Oral Solid Tablet (Cross-scored to ensure safe, exact fractioning for personalized low-dose titration)
Packaging Configurations: 10 / 20 / 30 Tablets per Blister packed exclusively in high-barrier Alu-Alu (Cold-Form Foil) or deep-amber moisture-shield PVC/PVDC strips. Lorazepam is highly physically sensitive to light and moisture; our premium tropicalized opaque packaging completely isolates the active core, guaranteeing a full 36-month shelf life in hot, humid Zone IVb export environments.
Psychotropic Manufacturing Governance & Quality Control
Strict Psychotropic Containment Isolation: Because Lorazepam is a highly potent controlled psychotropic substance, our manufacturing execution occurs inside Dedicated, Negative-Pressure Isolation Suites (Schedule X Standards). These blocks run on fully independent, HEPA-filtered HVAC infrastructure, physically preventing active chemical crossover and matching rigid international regulatory audits.
Microgram Dosing Content Uniformity: Since Lorazepam is compressed at exceptionally low active doses (0.5 mg to 2.0 mg) relative to the total mass of the tablet core, we deploy Automated Geometric Multi-Stage Solid Blending Suites. This physically guarantees perfect chemical distribution across millions of units, eliminating dangerous under-dosing or toxic spikes.
Validated Release Kinetics: Every export production batch physically undergoes Automated In-Vitro Dissolution Profiling, chemically validating that our generic formulations achieve rapid gastric disintegration and precise bioequivalence to match global innovator references (such as Ativan).
Primary Indications
Psychiatry: Short-term management of severe Generalized Anxiety Disorders (GAD), panic attacks, and acute agitation associated with psychotic episodes.
Neurology & Emergency Medicine: Adjuvant management of Status Epilepticus (continuous seizures) and termination of acute febrile convulsions.
Addiction Medicine: Control of acute, severe symptoms associated with Alcohol Withdrawal Syndrome, including delirium tremens and withdrawal seizures.
Anesthesiology Support: Pre-operative medication to induce light sedation, alleviate situational anxiety, and produce anterograde amnesia prior to surgical intervention.
Usage Instructions
The Short-Term Utilization Mandate: Lorazepam is clinically optimized for short-term intervention (typically 2 to 4 weeks). Prolonged, unmonitored chronic usage can chemically induce physiological dependence and tolerance.
The Tapered Cessation Protocol: Advise clinical and pharmacy networks that patients on continuous daily management must NEVER halt this medication abruptly. Sudden withdrawal can chemically destabilize central GABA networks, physically triggering severe rebound anxiety, insomnia, tremors, or life-threatening withdrawal seizures. Doses must be progressively tapered down under direct specialist observation.
Central Depressant Interaction Warning: Patients must strictly avoid consuming alcohol, barbiturates, or opioid analgesics alongside Lorazepam. Co-administration chemically multiplies central nervous system depression, physically risking severe respiratory depression, profound coma, or death.
Safety Warning: POTENT SCHEDULED PSYCHOTROPIC SUBSTANCE. Controlled Drug Class — For Psychiatry and Neurology Specialist Supervision Only. Dependence Risk: Prolonged usage carries a high chemical risk of physiological and psychological Habituation and Dependence; execute absolute compliance tracking. Respiratory Safety Note: May physically depress central respiratory drive; monitor respiratory parameters closely in patients presenting with compromised pulmonary architecture. Contraindications: Absolute contraindications in patients presenting with acute respiratory insufficiency, severe sleep apnea syndrome, myasthenia gravis, severe hepatic failure (risk of precipitating encephalopathy), or known hypersensitivity to benzodiazepine structures.
Controlled Global Supply Chain & CDMO Licensing
Healthy Life Pharma Private Limited and Healthy Inc provide fully compliant, internationally validated Third-Party Contract Manufacturing (CDMO Services) and bulk private-label export supply for the entire Lorazepam dosage spectrum. Operating under strict narcotics and controlled-substances authority clearances, we handle all mandatory international cross-border documentation (Official Ministry of Health Psychotropic Import Permits, Central Bureau of Narcotics – CBN Export Licenses, WHO-GMP Certificate, COPP, COA, and Complete CTD Format Registration Dossiers) for seamless import entry.
Commercial & Bulk Procurement Inquiries:
Corporate Head Office: Mumbai, Maharashtra, India
Primary Manufacturing Base: Boisar, Maharashtra, India
WhatsApp / Direct Regulatory Helpline: +91 7710003340
Controlled Substances Registry Email: info@healthyinc.co.in
